Application of rhenium-188 HEDP in bone metastases therapy

Radionuclide bone metastases therapy is a major achievement of nuclear medicine. Development of less radiotoxic and more effective radiopharmaceuticals is therefore a challenge for radiopharmacists and industry. This paper reviews the application of rhenium-188 HEDP as a reactor- or generator-produc...

Full description

Saved in:
Bibliographic Details
Published in:Nuclear medicine review. Central & Eastern Europe 2003, Vol.6 (1), p.55
Main Authors: Scheffler, Justyna, Derejko, Mirosława, Bandurski, Tomasz, Romanowicz, Grzegorz
Format: Article
Language:English
Subjects:
Bone Neoplasms - complications
Bone Neoplasms - radiotherapy
Bone Neoplasms - secondary
Etidronic Acid - adverse effects
Etidronic Acid - therapeutic use
Humans
Leukopenia - etiology
Organometallic Compounds
Pain - etiology
Pain - radiotherapy
Palliative Care - methods
Practice Patterns, Physicians
Radiopharmaceuticals - therapeutic use
Rhenium - adverse effects
Rhenium - therapeutic use
Thrombocytopenia - etiology
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Radionuclide bone metastases therapy is a major achievement of nuclear medicine. Development of less radiotoxic and more effective radiopharmaceuticals is therefore a challenge for radiopharmacists and industry. This paper reviews the application of rhenium-188 HEDP as a reactor- or generator-produced nuclide for bone metastases therapy.
ISSN:1506-9680